News
$3,350,000 of ELI LILLY AND COMPANY lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to intellectual ...
According to Eli Lilly data, the average out-of-pocket cost for the company’s insulin was about $17 per month in 2023. Texas Health Resources’ lawsuit is one of hundreds filed in the past ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...
13don MSN
Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.
The North Texas hospital system joins over 400 other entities and a dozen state attorneys general suing over alleged ...
shares surge Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek ...
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback